Article

ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 Trial

2021-11-17

Abstract excerpt

Darbepoetin alfa (DA) is often used in treating anemia of lower-risk (IPSS low or int-1) myelodysplastic syndromes (MDS). However, whether mutations can predict effectiveness of DA has not been examined. The present study aimed to determine gene mutations for predicting therapeutic effect of DA. Primary endpoint was correlation between the presence of highly frequent (≥10%) mutations and hematological improvement...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7b23cdf8-e24d-5d6b-8968-10207d3a7106
DOI: 10.21203/rs.3.rs-957642/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 TrialDOI 10.21203/rs.3.rs-957642/v1Read

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.Semantic proximity Read

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read

Mutations and karyotype predict treatment response in myelodysplastic syndromes.Semantic proximity Read

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.Semantic proximity Read

Therapy for lower-risk MDS.Semantic proximity Read

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read

Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes.Semantic proximity Read

Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) and the role of next‐generation sequencingSemantic proximity Read

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.Semantic proximity Read

[Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome].Semantic proximity Read

Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.Semantic proximity Read

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.Semantic proximity Read